AERI
Aerie Pharmaceuticals Inc (AERI)
$15.25--
Market is closedMarket is closed – opens on 8 PM, 12 Dec 2022
– opens on 8 PM, 12 Dec 2022
Key Stats
$15.24
Day's Range
$15.25
$4.81
52-Week Range
$15.37
| Returns | |
| 1 month return | 0.13% |
| 3 month return | 0.86% |
| 1 year return | 64.69% |
| 5 year return | 74.24% |
Company Information
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
| Organization | Aerie Pharmaceuticals Inc |
| Employees | 376 |
| CEO | Mr. Raj Kannan |
| Industry | Health Technology |
Analyst Recommendation
based on 9 analysts ratings
Buy
77%
Buy
11%
Hold
11%
Sell
Based on 9 Wall street analysts offering stock ratings for Aerie Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 0.46%Current
$15.25
Target
$15.32
Recommendation Trend
Based on 9 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 7 | 6 | 13 |
| Hold | 1 | 8 | 2 |
| Sell | 1 | 0 | 1 |
| Consensus | BUY | HOLD | BUY |
Company Financials
Highlights
| Market Capitalization | 753.6M |
| Book Value | $0.51 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.47 |
| PEG Ratio | 0.0 |
| Wall Street Target Price | 15.32 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 34.26 |
| Enterprise Value | 918.1M |
| Enterprise Value/Revenue | 4.29 |
| Enterprise Value/Ebitda | -350.17 |
Technicals
| Beta | -0.06 |
| 50 Day MA | 15.19 |
| 200 Day MA | 10.11 |
Institutional Holdings
Deerfield Management Co
9.82%
Vanguard Group Inc
5.5%
Bank of America Corp
5.26%
Jefferies Group Inc
4.78%
Schroder Investment Management Group
4.24%
UBS Group AG
3.46%
Discover more
Frequently Asked Questions
What is Aerie Pharmaceuticals Inc share price today?
Can Indians buy Aerie Pharmaceuticals Inc shares?
How can I buy Aerie Pharmaceuticals Inc shares from India?
Can Fractional shares of Aerie Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Aerie Pharmaceuticals Inc stocks?
What are today’s High and Low prices of Aerie Pharmaceuticals Inc?
What are today’s traded volumes of Aerie Pharmaceuticals Inc?
What is today’s market capitalisation of Aerie Pharmaceuticals Inc?
What is the 52 Week High and Low Range of Aerie Pharmaceuticals Inc?
How much percentage Aerie Pharmaceuticals Inc is down from its 52 Week High?
How much percentage Aerie Pharmaceuticals Inc is up from its 52 Week low?
What are the historical returns of Aerie Pharmaceuticals Inc?
Who is the Chief Executive Officer (CEO) of Aerie Pharmaceuticals Inc?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*